Updated on 4 March 2014
Mr Harry Rosen, Chief Executive Officer of Phosphagenics, said, "We welcome Lawrence, Geert and Nathan to our Board. They represent the new generation of well-credentialed directors who are committed to strong corporate governance with determination to create shareholder value.
"They join the Board on the cusp of Phosphagenics commercialising our lead product, the oxymorphone pain relief patch. Their commercialisation experience, contacts and advice will be invaluable during this transformational time.
Mr Gozlan said, "Nathan, Geert and I are delighted to join the Company at this time with such a compelling technology targeting large unmet medical needs. The results from the oxymorphone patch trial, announced in October, indicate the Company is well on the way to finalising development and commercialisation of this novel and valuable product. We look forward to continuing to revamp Phosphagenics and help drive commercialisation and also look forward to potential additions to the board and senior executive team in the future."